Background and Purpose: We examined the effect of ticlopidine hydrochloride on the enhanced
W e found recently' that activated platelets enhance erythrocyte aggregability in vitro and the monoclonal antibody against platelet thrombospondin lowers the erythrocyte aggregability. We further reported that erythrocyte aggregability was enhanced in patients with occlusive cerebrovascular disease (CVD).2 Antiplatelet agents may therefore influence the erythrocyte aggregability in patients with occlusive CVD. Ticlopidine hydrochloride possesses antiplatelet properties and has been used for the secondary prevention of cerebral infarction3 or the prevention of transient ischemic attacks. 4 The purpose of the present study was to examine the effect of ticlopidine on erythrocyte aggregability in patients with cerebral infarction during the chronic phase (over 1 month after onset).
Subjects and Methods We selected 24 patients with cerebral infarction during the chronic phase who visited our outpatient clinic at the Department of Neurology, Keio University, and who had not taken antiplatelet agents. These patients comprised 20 men and 4 women from 42 to 74 (mean+SD, 56±9) years of age. The diagnosis of cereReceived August 24, 1992; final revision received February 11, 1993 ; accepted March 11, 1993. From the Department of Neurology, School of Medicine, Keio University, Tokyo, Japan.
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bral infarction was based on clinical and brain computed tomographic (CT) findings. The time after onset of cerebral infarction at entry to the present study ranged from 2 to 24 (mean+SD, 6+6) months. The following risk factors for stroke were noted: hypertension in 10 patients, diabetes mellitus in 5, hyperlipidemia in 2, and a smoking habit in 6. The patients were randomly assigned to the ticlopidine-treated group (n= 14) In each of the study participants, 10 ml venous blood was obtained from the antecubital vein, and 1.1 mg/ml ethylenediaminetetraacetic acid (EDTA) was added as an anticoagulant. We used 1 ml to measure the erythrocyte aggregation rate (aggregability) with the whole-blood erythrocyte aggregometer that we developed.5 Briefly, blood introduced into a transparent tube (0.26-cm ID) was automatically subjected to a shear rate of approximately 500 s-1 followed by a sudden stoppage. The subsequent changes in optical density of the blood due to the formation of erythrocyte aggregates were recorded with an apparatus utilizing infrared light and a silicon photodiode. From the resultant so-called aggregogram, the erythrocyte aggregation rate was calculated as the rate constant of the monoexponential curve during the initial 20 seconds using the mathematical strategy reported by us previously.5 The remainder of the blood sample was used to measure the levels of hemoglobin; the hematocrit; erythrocyte and leukocyte cell counts; platelet count; concentrations of total protein, albumin, globulin, and fibrinogen; and the albumin-globulin (A/G) ratio. The rapid physiological coagulation method was used for the determination of fibrinogen. The A/G ratio was calculated from the values of the total protein and albumin. The evaluators of the erythrocyte aggregability were not informed as to whether the blood samples to be tested were from the ticlopidine-treated group, the control group, or normal subjects.
The data are presented as mean±SD. Statistical analysis was performed by one-way analysis of variance (ANOVA) for repeated measurements and Bonferroni's modified t test, with a minimum acceptable value of P<.05.
Results
The changes in erythrocyte aggregability in both patient groups (the ticlopidine and control groups) and the erythrocyte aggregability in the age-matched healthy volunteers (normal subjects) are shown in the Figure. The values for the erythrocyte aggregability of the ticlopidine group (0.147±0.017/s) and the control group (0.147±0.018/s) at the initiation of the study were significantly higher (P<.05 for both) than those of the normal subjects (0.123±0.021/s). In the ticlopidine group, the mean values of erythrocyte aggregability were 0.147±0.017/s, 0.138±0.019/s, and 0.133±0.018/s before, at 4 weeks after, and 8 weeks after the initiation of ticlopidine administration, respectively. One-way ANOVA revealed significant differences among the mean values of erythrocyte aggregability in the ticlopidine group (P<.0002). Furthermore, the erythrocyte aggregability values at 4 and 8 weeks after ticlopidine administration were significantly lower than those before administration (P<.05 for both). The erythrocyte Graph shows changes in erythrocyte aggregation rate (aggregability) in the ticlopidine-treated group (n=14, *) and control group (n=10, o). The mean +SD enhanced erythrocyte aggregability in the ticlopidine group was significantly reduced at 4 weeks and 8 weeks after ticlopidine administration (P<.05 by Bonferroni's modified t test), whereas erythrocyte aggregability underwent no significant change for 8 weeks in the control group. Erythrocyte aggregability at 8 weeks after ticlopidine administration was significantly lower (P<.05) than that in the control group. All values before, at 4 weeks, and at 8 weeks in both groups (except that at 8 weeks in the ticlopidine group) were significantly higher (P<.05) than those in normal subjects. *P<.05 vs value before ticlopidine administration; tP<.05 vs value in control group. aggregability values at 8 weeks after ticlopidine administration did not show significant differences from the values in the age-matched normal subjects. On the other hand, the erythrocyte aggregability values in the control group underwent no significant change during the 8-weeks period (0.147+0.018/s, 0.146±0.016/s, and 0.148±0.017/s at the first, second, and third measurements, respectively). The erythrocyte aggregability value at 8 weeks in the ticlopidine-treated group (0.133±0.018/s) was significantly lower (P<.05) than that in the control group (0.148±0.017/s).
The laboratory data for the ticlopidine-treated group compared with normal subjects are summarized in Table 1 ; data for the control group compared with normal subjects are in Table 2 . One-way ANOVA revealed significant differences among the mean values of the levels of hemoglobin, hematocrit, erythrocyte count, and fibrinogen concentration (P<.0003, P<.0017, P<.0019, and P<.0051, respectively) in the ticlopidine-treated group. Slight but significant decreases in the hemoglobin, hematocrit, and erythrocyte count were noted at 4 weeks and 8 weeks after ticlopidine administration. The fibrinogen concentration (290 mg/dl) was also decreased at 4 weeks (265 mg/dl; P<.05) and 8 weeks (255 mg/dl; P<.05) after ticlopidine administration. The concentrations of total protein, albumin, and globulin and the A/G ratio did not vary significantly after ticlopidine administration. In the control group, there were no significant changes in laboratory data over the period of In a previous communication,2 we reported that the enhanced erythrocyte aggregability occurring in the acute phase of cerebral infarction became reduced in the chronic phase. The data obtained in the present control group excluded the possibility that the change in the ticlopidine group could be accounted for as part of the natural course following a cerebral infarction. The possible mechanisms underlying such a reduction in erythrocyte aggregability (or "improvement" of the erythrocyte aggregability) after ticlopidine administration could be both intrinsic and extrinsic to the erythrocytes. First, direct effects of ticlopidine on the erythrocytes should be considered. The possible changes may include modifications of their shape, deformability, negative surface charge, affinity to macromolecules, and membrane constituents. We have found that ticlopidine exerts a direct inhibitory effect on erythrocyte aggregability, based on measurements of the erythrocyte aggregation rate before and at 15 minutes after addition of ticlopidine to venous blood sampled from healthy human volunteers (N. Tanahashi, unpublished observations). Ticlopidine may also cause some intrinsic physiological changes in the erythrocytes or permeability of the erythrocyte cell membrane.
Second, changes in fibrinogen concentration may be involved because the fibrinogen concentration is known to be closely related to the erythrocyte aggregability.7-9 In the present study, the fibrinogen concentration underwent a significant reduction after ticlopidine administration (9% at 4 weeks and 10% at 8 weeks). Improvement of erythrocyte hyperaggregability by ticlopidine could thus be attributed partly to a reduction of fibrinogen. Lowering of the plasma fibrinogen concentration by ticlopidine to the same degree as in the present study has been reported in peripheral arterial disease10-1 and occlusive CVD.15,'6 Although the reasons for the reduction in plasma fibrinogen concentration by ticlopidine remain unclear, the effect of ticlopidine on the binding of fibrinogen to platelets'2 or inhibition of new thrombus formation in the vessel walls through inhibition of platelet aggregation may be considered a possible cause. The third mechanism that could affect erythrocyte aggregability is the secondary effect of an inhibition of platelet aggregation. We found recently that platelet activation causes enhancement of the erythrocyte aggregability, which suggests a possible role for the released granular contents of activated platelets. In patients with occlusive CVD, activation of platelets progresses in the occluded arteries with thrombosis or stenotic arteries; thrombospondin, f3-thromboglobulin, serotonin, etc, are released from the platelet granules into the circulating blood. Among these substances, thrombospondin has been found to exert a strong lectin activity on fixed sheep erythrocytes.18 We also observed that the monoclonal antibody against platelet thrombospondin decreases the erythrocyte aggregation rate.1 It appears, therefore, that thrombospondin may participate in the control of erythrocyte aggregability in the circulating blood. If ticlopidine can reduce the substances released from activated platelets (including thrombospondin) by inhibiting platelet activation, it may affect the enhanced erythrocyte aggregability. The effect of ticlopidine on plasma thrombospondin is now under investigation.
